Cutaneous T-Cell Lymphoma Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com

Cutaneous T-Cell Lymphoma Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com




Cutaneous T-Cell Lymphoma Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cutaneous T-Cell Lymphoma – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This Cutaneous T-cell Lymphoma – Pipeline Insight, 2021 provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Cutaneous T-cell Lymphoma pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous T-cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Cutaneous T-cell Lymphoma.

Cutaneous T-cell Lymphoma Emerging Drugs Chapters

This segment of the Cutaneous T-cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cutaneous T-cell Lymphoma Emerging Drugs

Naloxone Hydrochloride: Elorac

Naloxone lotion is an investigational opiate antagonist designed to relieve pruritus associated with CTCL. The drug is currently in Phase III clinical evaluation for the treatment of cutaneous T-cell lymphoma. Elorac received Orphan Drug Designation for naloxone hydrochloride lotion from both FDA and the European Medicines Agency. Elorac also has Fast Track designation from FDA for this novel investigational new drug.

Cobomarsen: Viridian Therapeutics

Cobomarsen is an inhibitor of microRNA-155. microRNA-155 is believed to play an important role in the proliferation and survival of malignant cancer cells in certain types of blood cancer. The drug is currently in Phase II clinical evaluation for the treatment of Cutaneous T-cell Lymphoma (CTCL). On 23rd July 2020, miRagen Therapeutics (now Viridian Therapeutics) announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma.

Cutaneous T-cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Cutaneous T-cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cutaneous T-cell Lymphoma

There are approx. 25+ key companies which are developing the therapies for Cutaneous T-cell Lymphoma. The companies which have their Cutaneous T-cell Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Elorac.

Phases

This report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Cutaneous T-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cutaneous T-cell Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous T-cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous T-cell Lymphoma drugs.

Cutaneous T-cell Lymphoma Report Insights

  • Cutaneous T-cell Lymphoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Cutaneous T-cell Lymphoma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Cutaneous T-cell Lymphoma drugs?
  • How many Cutaneous T-cell Lymphoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cutaneous T-cell Lymphoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cutaneous T-cell Lymphoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cutaneous T-cell Lymphoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Soligenix
  • Elorac
  • 4SC AG
  • Merck Sharp & Dohme Corp.
  • Innate Pharma
  • Viridian Therapeutics
  • Sorrento Therapeutics
  • Bio-Path Holdings, Inc.
  • Legend Biotech USA Inc.
  • Genzada Pharmaceuticals
  • VidacPharma
  • Medc Biopharma

Key Products

  • SGX 301
  • Naloxone Hydrochloride
  • Resminostat
  • Letermovir
  • IPH4102
  • Cobomarsen
  • Sofusa anti-PD1
  • L-Bcl-2 antisense oligonucleotide
  • LB1901
  • GZ17-6.02
  • VDA-1102
  • MDC 2021

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/zb8fi3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900